Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

1.56
-0.0700-4.29%
Post-market: 1.580.0200+1.28%19:50 EDT
Volume:244.11K
Turnover:376.02K
Market Cap:7.47M
PE:-0.59
High:1.60
Open:1.57
Low:1.49
Close:1.63
52wk High:2.68
52wk Low:0.8400
Shares:4.79M
Float Shares:4.78M
Volume Ratio:1.48
T/O Rate:5.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6287
EPS(LYR):-11.3245
ROE:-373.18%
ROA:-163.99%
PB:10.19
PE(LYR):-0.14

Loading ...

Alzamend reports encouraging Phase II brain MRS data for AL001 lithium therapy

Reuters
·
Apr 07

Alzamend Neuro Reports Encouraging Pharmacodynamic Data From Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

THOMSON REUTERS
·
Apr 07

Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate

Reuters
·
Mar 26

Alzamend Neuro Reports Positive Topline Data From Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study; Al001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Al001 Shows Higher Lithium Concentrations in All Measured Brain Regions

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Initiates Second Phase Ii Trial in Bd Patients; Topline Data Expected Q3 2026

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Additional Phase Ii Studies in Mdd, Ptsd, Alzheimer's Expected to Begin in Latter Half of 2026

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Al001 Delivers 101% Total Lithium Blood Exposure, 97% Peak Levels VS Standard Carbonate

THOMSON REUTERS
·
Mar 26

Alzamend Neuro faces Nasdaq delisting risk as stockholders’ equity falls to 2.2 million USD

Reuters
·
Mar 21

BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital

Reuters
·
Mar 16

Alzamend Neuro Inc reports results for the quarter ended January 31 - Earnings Summary

Reuters
·
Mar 12

Alzamend Neuro Q3 net loss widens 112% to USD 2.2 million

Reuters
·
Mar 12

Alzamend Neuro Establishes ATM Equity Offering Agreement

TIPRANKS
·
Mar 07

BRIEF-Alzamend Neuro Inc - Enters ATM Sales Agreement To Sell Up To $3.0 Million In Common Stock - SEC Filing

Reuters
·
Mar 07

Alzamend Neuro Inc - Enters Atm Sales Agreement to Sell up to $3.0 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Mar 07

Alzamend Neuro Inc expected to post a loss of $1.92 a share - Earnings Preview

Reuters
·
Mar 07